Breaking News Instant updates and real-time market news.

PTGX

Protagonist Therapeutics

$8.35

-1.07 (-11.36%)

, LJPC

La Jolla

$2.59

-2.99 (-53.58%)

06:28
11/26/19
11/26
06:28
11/26/19
06:28

La Jolla failure a positive for Protagonist Therapeutics, says Nomura Instinet

La Jolla Pharmaceutical (LJPC), a Protagonist Therapeutics (PTGX) competitor, announced yesterday that it will reassess development of LJPC-401, its synthetic human hepcidin formulation, due to mixed clinical results, Nomura Instinet analyst Christopher Marai tells investors in a research note. The analyst views the news positively for Protagonist's competing drug, PTG-300. He keeps a Buy rating on Protagonist shares with a $29 price target.

PTGX

Protagonist Therapeutics

$8.35

-1.07 (-11.36%)

LJPC

La Jolla

$2.59

-2.99 (-53.58%)

PTGX Protagonist Therapeutics
$8.35

-1.07 (-11.36%)

05/09/19
STFL
05/09/19
UPGRADE
Target $17
STFL
Buy
Stifel upgrades Protagonist Therapeutics to Buy after Janssen opts in
Stifel analyst Adam Walsh last night upgraded Protagonist Therapeutics to Buy from Hold and raised his price target for the shares to $17 from $11. The expansion of the deal between Protagonist and Janssen for PTG-200 and other IL-23 receptor antagonists brings large pharma validation to the former's oral peptide platform, Walsh tells investors in a research note. The analyst now has increased confidence in PTG-200. Janssen's decision to opt-in to further PTG-200 development is supportive of PTG-200's potential in Crohn's and should assuage investor fears around Protagonist's oral peptide technology, says the analyst.
05/09/19
05/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Atlassian (TEAM) upgraded to Buy from Neutral at Goldman Sachs with Heather Bellini saying consensus billings expectations for Q4 of $361M, or up 30% year-over-year, appear conservative. 2. Match Group (MTCH) upgraded to Neutral from Sell at Goldman Sachs with 3ith analyst Michael Ng stating that the positive stock reaction to Match's in-line Q1 revenue and EBITDA results illustrate the market is more focused on the longer-term investment thesis. 3. Protagonist Therapeutics (PTGX) upgraded to Buy from Hold at Stifel with analyst Adam Walsh saying yhe expansion of the deal between Protagonist and Janssen for PTG-200 and other IL-23 receptor antagonists brings large pharma validation to the former's oral peptide platform. 4. Penn National (PENN) upgraded to Buy from Neutral at BofA/Merrill with analyst Shaun Kelley stating that its core consumer remains stable and he believes catalysts such as the relaunch of MyChoice and sports betting are being underappreciated by investors. 5. Ferrari (RACE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas noting the company's better than expected Q1 results and saying he has higher conviction in the company's strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
HCWC
07/08/19
INITIATION
Target $23
HCWC
Buy
Protagonist Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao started Protagonist Therapeutics with a Buy rating and $23 price target. While Protagonist's pipeline remains relatively early stage, the Phase 2 data expected later this year for PTG-300 should be an important catalyst for shares since the data may cause investors to assign a much higher valuation to that program, especially as the company should begin work on a second indication, Tsao tells investors in a research note.
11/08/19
NOMU
11/08/19
NO CHANGE
Target $29
NOMU
Buy
Protagonist selloff yesterday a buying opportunity, says Nomura Instinet
Nomura Instinet analyst Christopher Marai views the selloff yesterday in shares of Protagonist Therapeutics as a buying opportunity into the PTG-300 data in Q4. The analyst reiterates a Buy rating on the shares with a $29 price target.
LJPC La Jolla
$2.59

-2.99 (-53.58%)

06/06/19
HCWC
06/06/19
NO CHANGE
HCWC
La Jolla price target raised to $27 from $25 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for La Jolla Pharmaceutical to $27 from $25 after the company announced positive data from its pre-specified interim analysis of the Phase 2 clinical study evaluating LJPC-401 in patients with hereditary hemochromatosis. The analyst increased his probability of success for LJPC-401 to 35% from 30% following the data and keeps a Buy rating on La Jolla shares.
06/07/19
RHCO
06/07/19
NO CHANGE
Target $20
RHCO
Buy
La Jolla opportunity for '401 to be expanded with HH patients, says SunTrust
SunTrust analyst Joon Lee kept his Buy rating and $20 price target on La Jolla, saying the stock price remains undervalued despite the 92% rally yesterday on the news that its phase 2 LJPC-401 study in hereditary hemochromatosis, or HH, resulted in "statistic significance". The analyst notes that some 640K - 1.6M HH patients exist in in the U.S., and given '401's superior efficacy and tolerability, its pricing may come at a premium relative to the $15K/year option for Exjade. Lee adds that the market assessment of HH prevalence is clouded by the tendency for the disease to be "under-diagnosed".
11/13/19
HCWC
11/13/19
NO CHANGE
Target $19
HCWC
Buy
La Jolla price target lowered to $19 from $27 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $19 from $27 citing reduced revenue estimates following the company's Q3 results. The company reported Giapreza U.S. net sales of $5.7M, below the analyst's estimate of $6.7M. However, he forecasts Q4 volume will pick up as Giapreza sales "appear to be seasonal due to the flu season." White keeps a Buy rating on La Jolla shares.
11/25/19
RHCO
11/25/19
DOWNGRADE
RHCO
Hold
La Jolla downgraded to Hold from Buy at SunTrust
SunTrust downgraded La Jolla to Hold from Buy.

TODAY'S FREE FLY STORIES

FMCC

Freddie Mac

$0.00

(0.00%)

21:42
12/05/19
12/05
21:42
12/05/19
21:42
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$47.16

1.88 (4.15%)

21:00
12/05/19
12/05
21:00
12/05/19
21:00
Syndicate
GDS Holdings 5.49M share Secondary priced at $45.50 »

JPMorgan, RBC Capital and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 06

    Dec

BIG

Big Lots

$19.17

-0.75 (-3.77%)

, GCO

Genesco

$36.94

0.38 (1.04%)

20:25
12/05/19
12/05
20:25
12/05/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BIG

Big Lots

$19.17

-0.75 (-3.77%)

GCO

Genesco

$36.94

0.38 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

UNVR

Univar

$23.15

0.22 (0.96%)

20:10
12/05/19
12/05
20:10
12/05/19
20:10
Hot Stocks
Univar to sell environmental sciences business to AEA Investors for $195M »

Univar announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$3.10

-0.195 (-5.93%)

20:04
12/05/19
12/05
20:04
12/05/19
20:04
Syndicate
Plug Power 40M share Secondary priced at $2.75 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RGLD

Royal Gold

$117.91

0.64 (0.55%)

, TECK

Teck Resources

$15.71

-0.11 (-0.70%)

20:03
12/05/19
12/05
20:03
12/05/19
20:03
Hot Stocks
Royal Gold updates on Andacollo Workers Union ratifying 36-month collective deal »

Royal Gold (RGLD)…

RGLD

Royal Gold

$117.91

0.64 (0.55%)

TECK

Teck Resources

$15.71

-0.11 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IR

Ingersoll-Rand

$128.95

1.405 (1.10%)

19:41
12/05/19
12/05
19:41
12/05/19
19:41
Upgrade
Ingersoll-Rand rating change at Wells Fargo »

Ingersoll-Rand upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$119.86

2.42 (2.06%)

19:06
12/05/19
12/05
19:06
12/05/19
19:06
Hot Stocks
Intercept Phase 3 study for OCA in fibrosis patients published in The Lancet »

Intercept announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

HUN

Huntsman

$22.34

0.37 (1.68%)

18:52
12/05/19
12/05
18:52
12/05/19
18:52
Hot Stocks
Huntsman acquires Icynene-Lapolla for all-cash payment of $350M »

Huntsman announces its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

UBER

Uber

$28.65

-0.405 (-1.39%)

18:48
12/05/19
12/05
18:48
12/05/19
18:48
Hot Stocks
Uber: Non-consensual kissing of sexual body part reported in 1 in 3M U.S. trips »

Uber released its Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.65

-0.405 (-1.39%)

18:45
12/05/19
12/05
18:45
12/05/19
18:45
Hot Stocks
Uber says fatal physical assault reported in 1 in every 122M U.S. trips »

Uber released its Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOMO

Domo

$19.47

-0.19 (-0.97%)

, EZPW

Ezcorp

$5.21

-0.01 (-0.19%)

18:44
12/05/19
12/05
18:44
12/05/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Domo…

DOMO

Domo

$19.47

-0.19 (-0.97%)

EZPW

Ezcorp

$5.21

-0.01 (-0.19%)

DOCU

DocuSign

$69.51

-0.465 (-0.66%)

ULTA

Ulta Beauty

$236.09

-3.27 (-1.37%)

ZUMZ

Zumiez

$30.63

0.67 (2.24%)

CLDR

Cloudera

$10.02

0.16 (1.62%)

MDLA

Medallia

$29.79

0.55 (1.88%)

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

AOBC

American Outdoor Brands

$9.42

0.38 (4.20%)

YEXT

Yext

$16.62

0.065 (0.39%)

PD

PagerDuty

$24.99

-0.66 (-2.57%)

SAIC

SAIC

$83.82

-0.57 (-0.68%)

ZM

Zoom Video

$69.73

-0.22 (-0.31%)

KFY

Korn/Ferry

$40.26

0.39 (0.98%)

COO

Cooper Companies

$313.10

1 (0.32%)

GWRE

Guidewire

$119.32

0.68 (0.57%)

OKTA

Okta

$119.18

-2.64 (-2.17%)

UBER

Uber

$28.65

-0.405 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 16

    Dec

  • 17

    Dec

  • 17

    Dec

UBER

Uber

$28.65

-0.405 (-1.39%)

18:43
12/05/19
12/05
18:43
12/05/19
18:43
Hot Stocks
Uber says 107 total fatalities in 2017-2018 reported in relation to Uber app »

Uber released its Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.65

-0.405 (-1.39%)

18:34
12/05/19
12/05
18:34
12/05/19
18:34
Periodicals
Breaking Periodicals news story on Uber »

Uber reports 3,000 sexual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$819.61

10.12 (1.25%)

18:33
12/05/19
12/05
18:33
12/05/19
18:33
Hot Stocks
Chipotle CEO: I took time to understand what makes us unique »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$26.02

0.36 (1.40%)

18:17
12/05/19
12/05
18:17
12/05/19
18:17
Hot Stocks
Rent-A-Center raises quarterly dividend to 29c from 25c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKH

Black Hills

$76.66

0.01 (0.01%)

18:02
12/05/19
12/05
18:02
12/05/19
18:02
Hot Stocks
Black Hills utilities receive approval to upsize Renewable Ready program »

Black Hills announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRIM

Primoris

$21.92

0.3 (1.39%)

18:02
12/05/19
12/05
18:02
12/05/19
18:02
Hot Stocks
Primoris awarded two pipeline contracts for over $45M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$35.94

-0.09 (-0.25%)

18:01
12/05/19
12/05
18:01
12/05/19
18:01
Hot Stocks
LeMaitre CFO sells 121K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLBK

Columbia Financial

$16.33

-0.24 (-1.45%)

18:01
12/05/19
12/05
18:01
12/05/19
18:01
Hot Stocks
Columbia Financial expands stock buyback to acquire additional 3M shares »

Columbia Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXS

Axis Capital

$58.42

0.31 (0.53%)

17:49
12/05/19
12/05
17:49
12/05/19
17:49
Hot Stocks
Axis Capital increases quarterly dividend 2.5% to 41c per share »

Axis Capital has declared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PZZA

Papa John's

$59.67

-0.53 (-0.88%)

17:48
12/05/19
12/05
17:48
12/05/19
17:48
Periodicals
Former Papa John's CEO files suit against ad firm, Bloomberg says »

Papa John's founder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

THG

Hanover Insurance

$133.80

0.52 (0.39%)

17:47
12/05/19
12/05
17:47
12/05/19
17:47
Hot Stocks
Hanover Insurance raises dividend to 65c/shr, announces $2.50 special dividend »

The Hanover Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

17:46
12/05/19
12/05
17:46
12/05/19
17:46
Hot Stocks
Biohaven Pharmaceutical issued patent relating to troriluzole »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$15.32

-0.48 (-3.04%)

17:45
12/05/19
12/05
17:45
12/05/19
17:45
Upgrade
Morgan Stanley upgrades Epizyme to Overweight ahead of lymphoma data »

Morgan Stanley analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.